Resource Tag: Accelerate Use of Real-World Data & Evidence
Patient Listening on Social Media for Patient-Focused Drug Development.
Patients, life science industry and regulatory authorities are united in their goal to reduce the disease burden of patients by closing remaining unmet needs. Patients have, however, not always been systematically and consistently involved in the drug development process. Recognizing this gap, regulatory bodies worldwide have initiated patient-focused drug development (PFDD) initiatives to foster a more systematic involvement of patients in the drug development process and to ensure that outcomes measured in clinical trials are truly relevant to patients and represent significant improvements to their quality of life.
Patient Listening on Social Media for Patient-Focused Drug Development
A synthesis of considerations from patients, industry and regulators
Strategic Priorities Update February 2024
Join us for this inaugural update on the newly formed Strategic Priorities of the Pistoia Alliance, followed by a 30 minutes Q&A with our panelists
Agenda
Dr Becky Upton, President of the Pistoia Alliance
- Introduction
Dr Christian Baber, Chief Portfolio Officer, Pistoia Alliance
- Strategic Priorities Overview
- Harnessing AI to Expedite R&D
- Delivering Data-Driven Value
Thierry Escudier, Portfolio Lead, Pistoia Alliance
- Accelerating Use of Real-World Data
- Sustainability Driven R&D
An extension of the BioAssay Ontology
An extension of the BioAssay Ontology to now include pharmacokinetic/pharmacodynamic terminology for the enrichment of scientific workflows
Medical Research Charities and Biopharmaceutical Companies as Partners in Patient-Centred R&D
The Pistoia Alliance gathered a number of UK MRCs focused on complex lifelong conditions. The group used workshops and an opinion questionnaire for a snapshot of how the charities believe their knowledge and patient experiences could contribute insights and efficiencies to commercial R&D.
Calls for life sciences to focus on patient centricity
The life sciences and healthcare industries should restructure around patient centricity, according to global not-for-profit the Pistoia Alliance.
The call follows a meeting at the Pistoia Alliance’s annual European conference in London where discussions around the sector’s position in the wake of the Covid-19 pandemic took place. Attendees at the meeting highlighted how advances in technology are helping patients become more empowered regarding their health.
Real-World Evidence – Leveraging AI And Analytics For Real Value And Lasting Impact
Real-world evidence is not new, but with advances in processes, technology, policy, and analytics, is becoming more accessible and usable. RWE is being used to drive real outcomes and lasting impact for pharma, patients/subjects, and other participants in the continuum of care. At the foundation of RWE is data – behaviors, patterns, computational biomarkers, phenotypic/genomic data, imaging, outcomes, and social determinants of health.
The RWE trends that are happening in life sciences and biological sciences are driven by
- Datafication is driven by the availability of diverse data – big, small, and everything in between
- Competitive advantages
- Reducing the time for regulatory approvals
- Cost and outcomes
While data and descriptive analytics have been in vogue for years, advances in processing RWE – in combination with RCTs via data science, machine/deep learning, and advanced analytics – are creating new value for Pharma companies across the board – not just in R&D and pharmacovigilance but also extending into economic value, sales & marketing, affordable therapies, and patient outcomes.
More importantly, with the success of these analytics and AI efforts, we will see an increasing appetite for more types of RWE – beyond EMRs, all-claims, and commercial data sets – into patient-reported experiences, wearables, at-home devices, and implants.
Creating value at scale and achieving lasting impact is important, doable, and repeatable. This presentation will provide practical recommendations on how to put this tsunami of RWE and data variety to work using the IMPACT framework.
We will conclude with a discussion of representative use cases that pharma and biotechnology organizations can use to move the needle from a product focus to customized/personalized therapies, precision medicine, and population health.
Speaker: Prashant Natarajan, Vice President of AI & Analytics Solutions, H2O.ai and Pistoia Alliance AI CoE Advisory Committee Member
Please note: This presentation was originally delivered during the Qiagen Digital Insights hackathon in February 2021 and is being shared with permission. All rights reserved.